Citiraj:
# LSD-Assisted Psychotherapy in the Treatment of Anxiety Secondary to Life-Threatening Illness
Principal Investigator: Peter Gasser, MD with co-therapist Barbara Speich, RN
Location: Solothurne, Switzerland
MAPS is proud to sponsor the first study of LSD in humans in over 35 years. This study, based in Switzerland, is currently enrolling subjects who have life-threatening illnesses and are experiencing associated anxiety. The study received final approval from the BAG (Swiss DEA) on December 5, 2007, final approval from the Ethics Committee (Swiss IRB equivalent) on October 30, 2007 and SwissMedic (Swiss FDA equivalent) clearance on November 8, 2007. The first subject was enrolled on April 23, 2008. This study will evaluate LSD-assisted psychotherapy in twelve subjects suffering from clinical anxiety associated with advanced-stage cancer and other life-threatening illnesses. Dr. Gasser's study will complement Dr. John Halpern's MAPS-initiated research investigating MDMA-assisted psychotherapy in advanced-stage cancer patients with anxiety and Dr. Charles Grob's Heffter-sponsored research investigating psilocybin-assisted psychotherapy in cancer patients with anxiety. We expect to complete this study in fall of 2010.
The study will cost $190,000, all of which has been raised
Memorandum of Understanding between MAPS and Dr. Gasser
Dr. Gasser's MAPS-sponsored LSD/Anxiety Protocol
Generous donations have been made by Robert Barnhart ($125,000), Kevin Herbert ($18,750), Vanja Palmers ($10,000), Fredi Muller (10,000 SF), Amanda Fielding (5000 Euros), Anonymous ($85,000), and Anonymous ($5,000). Thank you to all who contributed through book and art purchases as well!
Prijavite se
Registruj se
FAQ
Pretraga
).
